Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Colorectal Dis. 2020 Nov;22(11):1482-1495. doi: 10.1111/codi.15003. Epub 2020 Feb 27.
Peritoneal metastases from colorectal cancer confer the worst survival among all metastatic sites. The adoption of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can offer selected patients with isolated colorectal peritoneal metastases (CRPM) a favourable long-term survival. There are numerous factors postulated to influence survival in patients undergoing CRS and HIPEC. The aim of this study was to identify the key perioperative prognostic factors that influence survival in patients undergoing CRS and HIPEC for isolated CRPM.
A systematic review and meta-analysis were conducted to evaluate prognostic factors influencing survival in patients undergoing CRS and HIPEC for isolated CRPM.
Thirty-three studies fitted the inclusion criteria for the systematic review, with 25 studies included in the meta-analysis. On pooled analysis, incomplete cytoreduction, increasing peritoneal carcinoma index (PCI) and lymph node involvement were significantly associated with a worse survival. Additionally, a rectal primary [hazard ratio (HR) 1.93, 95% CI 1.10-3.37], adjuvant chemotherapy (HR 0.71, 95% CI 0.54-0.93) and perioperative grade III/IV morbidity (HR 1.59, 95% CI 1.17-2.16) were also found to significantly influence survival. Notably, tumour differentiation and signet ring cell histology did not influence survival on pooled analysis.
This meta-analysis confirms that in patients undergoing CRS and HIPEC for isolated CRPM, incomplete cytoreduction, high PCI and lymph node involvement have a negative influence on survival. In addition, a rectal primary, adjuvant chemotherapy use and grade III/IV morbidity are important factors that also significantly influence survival.
结直肠癌腹膜转移是所有转移部位中预后最差的。采用细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)可为孤立性结直肠腹膜转移(CRPM)的患者提供有利的长期生存。有许多因素被认为会影响接受 CRS 和 HIPEC 的患者的生存。本研究旨在确定影响接受 CRS 和 HIPEC 治疗孤立性 CRPM 患者生存的关键围手术期预后因素。
对评估影响接受 CRS 和 HIPEC 治疗孤立性 CRPM 患者生存的预后因素的研究进行了系统评价和荟萃分析。
共有 33 项研究符合系统评价的纳入标准,其中 25 项研究纳入荟萃分析。汇总分析显示,不完全肿瘤细胞减灭术、腹膜癌指数(PCI)升高和淋巴结受累与生存率降低显著相关。此外,直肠原发肿瘤[风险比(HR)1.93,95%可信区间(CI)1.10-3.37]、辅助化疗(HR 0.71,95%CI 0.54-0.93)和围手术期 III/IV 级发病率(HR 1.59,95%CI 1.17-2.16)也显著影响生存率。值得注意的是,肿瘤分化和印戒细胞组织学在汇总分析中对生存率没有影响。
本荟萃分析证实,在接受 CRS 和 HIPEC 治疗孤立性 CRPM 的患者中,不完全肿瘤细胞减灭术、高 PCI 和淋巴结受累对生存率有负面影响。此外,直肠原发肿瘤、辅助化疗的应用和 III/IV 级发病率是显著影响生存率的重要因素。